Home » Healthcare » Pharmaceuticals » Pharmacovigilance Market

Pharmacovigilance Market By Product Life Cycle (Pre-clinical, Phase I, Phase II, Phase III, Phase IV); By Type (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining); By Service Provider (In-house, Contract Outsourcing); By End-use (Pharmaceuticals, Biotechnology Companies, Medical Device Manufacturers, Others); By Process Flow (Case Data Management, Signal Detection, Risk Management System); By Therapeutic Area (Oncology, Neurology, Cardiology, Respiratory Systems, Others); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Pharmacovigilance Market Size 2023	USD 9,574.26 Million
Pharmacovigilance Market, CAGR	7.48%
Pharmacovigilance Market Size 2032	USD 18,325.43 Million

Market Overview

The Pharmacovigilance Market is projected to grow from USD 9,574.26 million in 2023 to USD 18,325.43 million by 2032, at a compound annual growth rate (CAGR) of 7.48%.

The Pharmacovigilance Market is driven by increasing regulatory requirements for drug safety, rising consumer awareness about adverse drug reactions, and the growing complexity of drug development processes. Enhanced focus on patient safety and the integration of advanced technologies like AI and big data analytics further support market expansion. Additionally, the increasing number of clinical trials and a higher incidence of chronic diseases globally contribute to the demand for robust pharmacovigilance systems. These factors collectively ensure rigorous monitoring and reporting of drug safety, bolstering the growth of the pharmacovigilance sector.

The Pharmacovigilance Market exhibits significant regional variations, with North America and Europe leading in market share due to stringent regulatory frameworks and advanced healthcare systems. Asia Pacific is emerging as a high-growth region due to expanding pharmaceutical industries and increasing awareness. Key players shaping the market include Accenture, IQVIA Inc., Cognizant, and ICON plc., who drive innovation and offer comprehensive pharmacovigilance solutions. These companies leverage their global reach and technological advancements to enhance drug safety monitoring and regulatory compliance across diverse geographies.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Drivers

Increasing Prevalence of Chronic Diseases

The growing incidence of chronic diseases, including diabetes, cardiovascular conditions, and cancer, is significantly driving the demand for medications. For instance, the CDC estimates that six in ten adults in the United States currently live with a chronic disease such as cancer, heart disease, or diabetes. As more individuals manage these conditions with prescribed treatments, there is a heightened need for effective pharmacovigilance to monitor medication safety. Rigorous safety monitoring becomes crucial to detect and address adverse drug reactions (ADRs), ensuring that the therapeutic benefits of medications outweigh potential risks. The increased reliance on drugs to manage chronic health issues underscores the necessity for comprehensive surveillance systems to safeguard patient well-being.

Rising Drug Development and Approval Rates

The pharmaceutical industry is experiencing a surge in drug innovation, with new medications continuously entering the market. For example, the Food and Drug Administration (FDA) approved 38 new drugs per year from 2010 through 2019, which is 60 percent more than the yearly average over the previous decade. This trend necessitates robust pharmacovigilance services to verify the safety and efficacy of these new drugs. Stringent regulatory frameworks mandate extensive pharmacovigilance activities as part of the drug approval process and ongoing post-market surveillance. As drug development accelerates, the need for thorough monitoring systems becomes more critical to comply with regulatory standards and ensure patient safety throughout the drug lifecycle.

Increasing Regulatory Scrutiny

Health authorities globally are imposing more stringent regulations on drug safety, compelling pharmaceutical companies to invest in comprehensive pharmacovigilance systems. This increased regulatory scrutiny is driven by a heightened focus on ensuring that drugs do not pose unforeseen risks to patients. Additionally, growing public awareness and concern about drug safety issues have intensified pressure on regulatory bodies to enforce rigorous safety standards. Companies must navigate this complex regulatory environment to maintain compliance and uphold their commitment to patient safety.

Advancements in Technology

Technological advancements, particularly in data analytics and artificial intelligence, are transforming the pharmacovigilance landscape. Big data analytics enables faster and more accurate identification of ADRs, enhancing the efficiency of safety monitoring processes. Moreover, the proliferation of digital health technologies, such as wearable devices and electronic health records, provides valuable data that supports pharmacovigilance efforts. These innovations facilitate more proactive and precise safety assessments, contributing to improved drug safety outcomes and advancing the field of pharmacovigilance.

Market Trends

Digital Transformation and Technological Advancements

The landscape of pharmacovigilance is being significantly reshaped by digital transformation, driven by the increasing availability of big data from various sources, including electronic health records, claims databases, and social media. For instance, the landscape of pharmacovigilance is being significantly reshaped by digital transformation, driven by the increasing availability of big data from various sources. These data-rich environments are enabling more sophisticated, data-driven insights into drug safety. Advanced analytics tools, powered by artificial intelligence (AI) and machine learning, are now being utilized to identify safety signals, predict adverse events, and optimize pharmacovigilance processes. AI algorithms analyze vast amounts of data to uncover patterns and predict potential risks, leading to more proactive safety measures and streamlined monitoring operations. This technological evolution is enhancing the accuracy and efficiency of pharmacovigilance, ensuring a more robust approach to drug safety.

Outsourcing Trends and Risk-Based Approaches

In response to the growing complexity of pharmacovigilance requirements, pharmaceutical companies are increasingly outsourcing these activities to specialized service providers. This trend is driven by the need to leverage external expertise and reduce operational costs. Outsourcing allows companies to tap into specialized knowledge and advanced technologies that may not be available in-house. Additionally, strategic partnerships between pharmaceutical companies, technology providers, and regulatory bodies are becoming more prevalent, aimed at addressing complex pharmacovigilance challenges collaboratively. Concurrently, the adoption of risk-based pharmacovigilance (RBPV) is gaining traction, focusing resources on drugs with higher safety risks. RBPV enhances efficiency and effectiveness by prioritizing safety monitoring based on the risk profile of various medications. This approach emphasizes proactive monitoring and risk mitigation strategies, improving overall drug safety and regulatory compliance.

Market Challenges Analysis

Data Quality, Completeness, and Privacy Concerns

A major challenge in pharmacovigilance is ensuring high data quality and completeness. Variability in data sources, including electronic health records, claims databases, and social media, can result in discrepancies in data quality and completeness. For instance, in the realm of data quality and completeness, a study titled “Pharmacovigilance in the Era of Big Data: Challenges and Opportunities” highlighted that one of the major challenges in leveraging big data for pharmacovigilance is ensuring data quality and reliability. Incomplete or missing data can significantly impede the identification and analysis of safety signals, leading to potential gaps in drug safety monitoring. Additionally, maintaining data privacy and security is paramount, as pharmacovigilance activities must adhere to stringent regulations such as GDPR and HIPAA. The risk of data breaches and unauthorized access to sensitive patient information poses a constant threat, necessitating robust security measures and compliance practices.

Global Harmonization and Technological Adoption Challenges

Efforts to harmonize pharmacovigilance regulations across different regions face challenges due to regulatory differences between countries. These discrepancies can complicate global safety monitoring and data sharing, as legal and technical barriers may hinder efficient cross-border data exchange. Furthermore, the adoption of emerging technologies, such as artificial intelligence and big data analytics, presents its own set of difficulties. Implementing these advanced technologies can be costly and require specialized technical expertise. Additionally, ethical considerations surrounding data privacy, bias, and transparency must be addressed to ensure responsible use of these technologies. Resource constraints, including budget limitations and a shortage of skilled professionals, exacerbate these challenges, making it difficult for pharmaceutical companies to invest in and maintain robust pharmacovigilance systems.

Market Segmentation Analysis:

By Product Life Cycle:

The Global Pharmacovigilance Market is segmented based on the product life cycle stages, including Pre-clinical, Phase I, Phase II, Phase III, and Phase IV. Each phase requires distinct pharmacovigilance activities to ensure drug safety and efficacy. The Pre-clinical phase involves initial safety assessments and toxicity studies before human trials. In Phase I, pharmacovigilance focuses on early safety data from a small group of healthy volunteers or patients. Phase II extends to a larger patient population to further assess safety and efficacy. The critical Phase III involves large-scale trials to confirm the drug’s benefit-risk profile. Finally, Phase IV, or post-marketing surveillance, continues safety monitoring after the drug’s release, addressing long-term effects and rare adverse events.

By Type:

The market also segments based on reporting and monitoring types: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining. Spontaneous Reporting is the traditional method where healthcare professionals report adverse drug reactions voluntarily. Intensified ADR Reporting involves proactive measures to capture more detailed safety data. Targeted Spontaneous Reporting focuses on specific drugs or patient groups. Cohort Event Monitoring tracks safety across predefined patient groups, while EHR Mining leverages electronic health records for real-time data analysis. Each type offers unique insights and enhances the overall safety monitoring process, catering to various regulatory and research needs.

Segments:

Based on Product Life Cycle:

Pre-clinical
Phase I
Phase II
Phase III
Phase IV

Based on Type:

Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

Based on Service Provider:

In-house
Contract Outsourcing

Based on End-use:

Pharmaceuticals
Biotechnology Companies
Medical Device Manufacturers
Others

Based on Process Flow:

Case Data Management
Case Logging
Case Data Analysis
Medical Reviewing & Reporting
Signal Detection
Adverse Event Logging
Adverse Event Analysis
Adverse Event Review & Reporting
Risk Management System
Risk Evaluation System
Risk Mitigation System

Based on Therapeutic Area:

Oncology
Neurology
Cardiology
Respiratory Systems
Others

Based on the Geography:

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Regional Analysis

North America

North America commands a substantial market share of approximately 40% in the global pharmacovigilance industry. This leadership position stems from the region’s robust pharmaceutical and biotechnology sectors, stringent regulatory environment, and advanced healthcare infrastructure. The United States, in particular, drives much of North America’s market growth, hosting numerous pharmaceutical giants, contract research organizations, and innovative biotech firms. These entities leverage cutting-edge technologies, including artificial intelligence and big data analytics, to enhance drug safety monitoring and adverse event reporting. North American pharmacovigilance practices benefit from significant investment in research and development, as well as a highly skilled workforce trained in the latest safety monitoring methodologies. The region’s market is characterized by a strong emphasis on post-marketing surveillance and real-world evidence gathering, driven by regulatory requirements and a growing focus on patient-centric healthcare.

Europe

Europe holds a significant market share of about 30% in the global pharmacovigilance sector, demonstrating a commitment to drug safety and regulatory excellence. Countries like Germany, the United Kingdom, and Switzerland lead the European market, benefiting from a well-established pharmaceutical industry and harmonized regulatory framework under the European Medicines Agency (EMA). European pharmacovigilance practices are distinguished by their comprehensive approach, encompassing both traditional and innovative methods of safety signal detection. The region excels in developing and implementing risk management plans, with a particular focus on proactive safety measures throughout the drug lifecycle. Europe’s pharmacovigilance market also benefits from strong collaboration between academic institutions, healthcare providers, and pharmaceutical companies, fostering the development of novel pharmacovigilance strategies. The continent’s emphasis on data privacy and security, exemplified by regulations like GDPR, has led to the creation of robust systems for handling sensitive patient information in pharmacovigilance activities.

Key Player Analysis

Accenture
IQVIA Inc.
Cognizant
Clinquest Group B.V. (Linical Americas)
IBM
Laboratory Corporation of America Holdings
ArisGlobal
Capgemini
ITClinical
ICON plc.
TAKE Solutions Limited
Parexel International (MA) Corporation
Wipro
United BioSource LLC
BioClinica Inc. (Clario)
ClinChoice (formerly FMD K&L)

Competitive Analysis

The Global Pharmacovigilance Market is highly competitive, with key players including Accenture, IQVIA Inc., Cognizant, ICON plc., Clinquest Group B.V. (Linical Americas), and Parexel International (MA) Corporation. These leading firms leverage their extensive industry experience and technological expertise to offer comprehensive pharmacovigilance solutions. They are continuously enhancing their service portfolios by incorporating advanced technologies like artificial intelligence and big data analytics to improve drug safety and regulatory compliance. The market competition is driven by their innovation in risk management, data analysis, and regulatory adherence, positioning them to effectively meet the increasing demand for robust pharmacovigilance systems across various therapeutic areas. Their strategic initiatives, including mergers and acquisitions, further strengthen their market position and operational capabilities.

Recent Developments

In January 2024, Accenture made a strategic investment in QuantHealth, an AI-powered clinical trial design company that simulates clinical trials in the cloud.
In August 2024, Cognizant completed its acquisition of Belcan, a global supplier of Engineering Research & Development (ER&D) services.
In 2024, IQVIA released a white paper discussing the impact of AI and regulatory changes on the pharmaceutical industry, with insights on the role of Generative AI in drug development and pharmacovigilance.
In March 2024, ArisGlobal announced three cutting-edge product offerings that will transform pharmacovigilance and regulatory operations.

Market Concentration & Characteristics

The Global Pharmacovigilance Market exhibits moderate to high market concentration, with a few leading players dominating the landscape. Major firms such as Accenture, IQVIA Inc., and Cognizant significantly influence market dynamics through their extensive service offerings and advanced technological capabilities. The market is characterized by a blend of established multinational corporations and specialized service providers, contributing to a competitive environment. Key characteristics include a focus on integrating cutting-edge technologies like artificial intelligence and big data analytics into pharmacovigilance processes to enhance safety monitoring and regulatory compliance. Companies are also increasingly adopting outsourcing strategies to leverage specialized expertise and reduce operational costs. This concentration and specialization drive continuous innovation and improvements in drug safety management, ensuring that pharmacovigilance practices align with evolving regulatory standards and industry demands.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Product Life Cycle, Type, Service Provider, End-use, Process Flow, Therapeutic Area and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The Global Pharmacovigilance Market is expected to grow significantly as the demand for comprehensive drug safety monitoring intensifies.
Advancements in artificial intelligence and machine learning will increasingly drive efficiency in adverse event detection and analysis.
The integration of big data analytics will enhance the ability to identify and manage safety signals more effectively.
Regulatory pressures will continue to escalate, pushing companies to adopt more robust and compliant pharmacovigilance systems.
The rise of digital health technologies will provide valuable data sources, contributing to improved pharmacovigilance practices.
Outsourcing pharmacovigilance activities will become more prevalent as companies seek cost-effective and specialized services.
Increased global collaboration will facilitate better data sharing and harmonization of pharmacovigilance practices across different regions.
The growing emphasis on patient-centric approaches will drive more proactive safety monitoring and reporting.
Emerging markets will present new opportunities and challenges as regulatory frameworks and industry practices evolve.
Continuous innovation and adaptation to evolving technologies and regulations will be critical for maintaining effective drug safety management.

Table of Content
CHAPTER NO. 1 : INTRODUCTION 24
1.1.1. Report Description 24
Purpose of the Report 24
USP & Key Offerings 24
1.1.2. Key Benefits for Stakeholders 24
1.1.3. Target Audience 25
1.1.4. Report Scope 25
CHAPTER NO. 2 : EXECUTIVE SUMMARY 26
2.1. Pharmacovigilance Market Snapshot 26
2.1.1. Global Pharmacovigilance Market, 2018 – 2032 (USD Million) 28
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 29
3.1. Russia-Ukraine and Israel-Palestine War Impacts 29
CHAPTER NO. 4 : PHARMACOVIGILANCE MARKET – INDUSTRY ANALYSIS 30
4.1. Introduction 30
4.2. Market Drivers 31
4.2.1. Driving Factor 1 Analysis 31
4.2.2. Driving Factor 2 Analysis 32
4.3. Market Restraints 33
4.3.1. Restraining Factor Analysis 33
4.4. Market Opportunities 34
4.4.1. Market Opportunity Analysis 34
4.5. Porter’s Five Forces Analysis 35
CHAPTER NO. 5 : ANALYSIS COMPETITIVE LANDSCAPE 36
5.1. Company Market Share Analysis – 2023 36
5.1.1. Global Pharmacovigilance Market: Company Market Share, by Volume, 2023 36
5.1.2. Global Pharmacovigilance Market: Company Market Share, by Revenue, 2023 37
5.1.3. Global Pharmacovigilance Market: Top 6 Company Market Share, by Revenue, 2023 37
5.1.4. Global Pharmacovigilance Market: Top 3 Company Market Share, by Revenue, 2023 38
5.2. Global Pharmacovigilance Market Company Revenue Market Share, 2023 39
5.3. Company Assessment Metrics, 2023 40
5.3.1. Stars 40
5.3.2. Emerging Leaders 40
5.3.3. Pervasive Players 40
5.3.4. Participants 40
5.4. Start-ups /SMEs Assessment Metrics, 2023 40
5.4.1. Progressive Companies 40
5.4.2. Responsive Companies 40
5.4.3. Dynamic Companies 40
5.4.4. Starting Blocks 40
5.5. Strategic Developments 41
5.5.1. Acquisitions & Mergers 41
New Product Launch 41
Global Expansion 41
5.6. Key Players Product Matrix 42
CHAPTER NO. 6 : PESTEL & ADJACENT MARKET ANALYSIS 43
6.1. PESTEL 43
6.1.1. Political Factors 43
6.1.2. Economic Factors 43
6.1.3. Social Factors 43
6.1.4. Technological Factors 43
6.1.5. Environmental Factors 43
6.1.6. Legal Factors 43
6.2. Adjacent Market Analysis 43
CHAPTER NO. 7 : PHARMACOVIGILANCE MARKET – BY PRODUCT LIFE CYCLE SEGMENT ANALYSIS 44
7.1. Pharmacovigilance Market Overview, by Product Life Cycle Segment 44
7.1.1. Pharmacovigilance Market Revenue Share, By Product Life Cycle, 2023 & 2032 45
7.1.2. Pharmacovigilance Market Attractiveness Analysis, By Product Life Cycle 46
7.1.3. Incremental Revenue Growth Opportunity, by Product Life Cycle, 2024 – 2032 46
7.1.4. Pharmacovigilance Market Revenue, By Product Life Cycle, 2018, 2023, 2027 & 2032 47
7.2. Pre-clinical 48
7.3. Phase I 49
7.4. Phase II 50
7.5. Phase III 51
7.6. Phase IV 52
CHAPTER NO. 8 : PHARMACOVIGILANCE MARKET – BY TYPE SEGMENT ANALYSIS 53
8.1. Pharmacovigilance Market Overview, by Type Segment 53
8.1.1. Pharmacovigilance Market Revenue Share, By Type, 2023 & 2032 54
8.1.2. Pharmacovigilance Market Attractiveness Analysis, By Type 55
8.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 55
8.1.4. Pharmacovigilance Market Revenue, By Type, 2018, 2023, 2027 & 2032 56
8.2. Spontaneous Reporting 57
8.3. Intensified ADR Reporting 58
8.4. Targeted Spontaneous Reporting 59
8.5. Cohort Event Monitoring 60
8.6. EHR Mining 61
CHAPTER NO. 9 : PHARMACOVIGILANCE MARKET – BY SERVICE PROVIDER SEGMENT ANALYSIS 62
9.1. Pharmacovigilance Market Overview, by Service Provider Segment 62
9.1.1. Pharmacovigilance Market Revenue Share, By Service Provider, 2023 & 2032 63
9.1.2. Pharmacovigilance Market Attractiveness Analysis, By Service Provider 64
9.1.3. Incremental Revenue Growth Opportunity, by Service Provider, 2024 – 2032 64
9.1.4. Pharmacovigilance Market Revenue, By Service Provider, 2018, 2023, 2027 & 2032 65
9.2. In-house 66
9.3. Contract Outsourcing 67
CHAPTER NO. 10 : PHARMACOVIGILANCE MARKET – BY END-USE SEGMENT ANALYSIS 68
10.1. Pharmacovigilance Market Overview, by End-use Segment 68
10.1.1. Pharmacovigilance Market Revenue Share, By End-use, 2023 & 2032 69
10.1.2. Pharmacovigilance Market Attractiveness Analysis, By End-use 70
10.1.3. Incremental Revenue Growth Opportunity, by End-use, 2024 – 2032 70
10.1.4. Pharmacovigilance Market Revenue, By End-use, 2018, 2023, 2027 & 2032 71
10.2. Pharmaceuticals 72
10.3. Biotechnology Companies 73
10.4. Medical Device Manufacturers 74
10.5. Others 75
CHAPTER NO. 11 : PHARMACOVIGILANCE MARKET – BY PROCESS FLOW SEGMENT ANALYSIS 76
11.1. Pharmacovigilance Market Overview, by Process Flow Segment 76
11.1.1. Pharmacovigilance Market Revenue Share, By Process Flow, 2023 & 2032 77
11.1.2. Pharmacovigilance Market Attractiveness Analysis, By Process Flow 78
11.1.3. Incremental Revenue Growth Opportunity, by Process Flow, 2024 – 2032 78
11.1.4. Pharmacovigilance Market Revenue, By Process Flow, 2018, 2023, 2027 & 2032 79
11.2. Case Data Management 80
11.2.1. Case Logging 80
11.2.2. Case Data Analysis 81
11.2.3. Medical Reviewing & Reporting 81
11.3. Signal Detection 82
11.3.1. Adverse Event Logging 82
11.3.2. Adverse Event Analysis 83
11.3.3. Adverse Event Review & Reporting 83
11.4. Risk Management System 84
11.4.1. Risk Evaluation System 84
11.4.2. Risk Mitigation System 85
CHAPTER NO. 12 : PHARMACOVIGILANCE MARKET – BY THERAPEUTIC AREA SEGMENT ANALYSIS 86
12.1. Pharmacovigilance Market Overview, by Therapeutic Area Segment 86
12.1.1. Pharmacovigilance Market Revenue Share, By Therapeutic Area, 2023 & 2032 87
12.1.2. Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area 88
12.1.3. Incremental Revenue Growth Opportunity, by Therapeutic Area, 2024 – 2032 88
12.1.4. Pharmacovigilance Market Revenue, By Therapeutic Area, 2018, 2023, 2027 & 2032 89
12.2. Oncology 90
12.3. Neurology 91
12.4. Cardiology 92
12.5. Respiratory Systems 93
12.6. Others 94
CHAPTER NO. 13 : PHARMACOVIGILANCE MARKET – GLOBAL ANALYSIS 95
13.1. Product Life Cycle 95
13.1.1. Global Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 95
13.1.2. Global Pharmacovigilance Market Revenue, By Product Life Cycle, 2024 – 2032 (USD Million) 95
13.2. Type 96
13.2.1. Global Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 96
13.2.2. Global Pharmacovigilance Market Revenue, By Type, 2024 – 2032 (USD Million) 96
13.3. Service Provider 97
13.3.1. Global Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 97
13.3.2. Global Pharmacovigilance Market Revenue, By Service Provider, 2024 – 2032 (USD Million) 97
13.4. End-use 98
13.4.1. Global Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 98
13.4.2. Global Pharmacovigilance Market Revenue, By End-use, 2024 – 2032 (USD Million) 98
13.5. Process Flow 99
13.5.1. Global Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 99
13.5.2. Global Pharmacovigilance Market Revenue, By Process Flow, 2024 – 2032 (USD Million) 99
13.6. Therapeutic Area 100
13.6.1. Global Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 100
13.6.2. Global Pharmacovigilance Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 100
CHAPTER NO. 14 : PHARMACOVIGILANCE MARKET – NORTH AMERICA 101
14.1. North America 101
14.1.1. Key Highlights 101
14.1.2. North America Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 102
14.1.3. North America Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 103
14.1.4. North America Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 104
14.1.5. North America Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 105
14.1.6. North America Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 106
14.1.7. North America Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 107
14.1.8. North America Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 108
14.2. U.S. 109
14.3. Canada 109
14.4. Mexico 109
CHAPTER NO. 15 : PHARMACOVIGILANCE MARKET – EUROPE 110
15.1. Europe 110
15.1.1. Key Highlights 110
15.1.2. Europe Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 111
15.1.3. Europe Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 112
15.1.4. Europe Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 113
15.1.5. Europe Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 114
15.1.6. Europe Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 115
15.1.7. Europe Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 116
15.1.8. Europe Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 117
15.2. UK 118
15.3. France 118
15.4. Germany 118
15.5. Italy 118
15.6. Spain 118
15.7. Russia 118
15.8. Belgium 118
15.9. Netherland 118
15.10. Austria 118
15.11. Sweden 118
15.12. Poland 118
15.13. Denmark 118
15.14. Switzerland 118
15.15. Rest of Europe 118
CHAPTER NO. 16 : PHARMACOVIGILANCE MARKET – ASIA PACIFIC 119
16.1. Asia Pacific 119
16.1.1. Key Highlights 119
16.1.2. Asia Pacific Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 120
16.1.3. Asia Pacific Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 121
16.1.4. Asia Pacific Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 122
16.1.5. Asia Pacific Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 123
16.1.6. Asia Pacific Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 124
16.1.7. Asia Pacific Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 125
16.1.8. Asia Pacific Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 126
16.2. China 127
16.3. Japan 127
16.4. South Korea 127
16.5. India 127
16.6. Australia 127
16.7. Thailand 127
16.8. Indonesia 127
16.9. Vietnam 127
16.10. Malaysia 127
16.11. Philippines 127
16.12. Taiwan 127
16.13. Rest of Asia Pacific 127
CHAPTER NO. 17 : PHARMACOVIGILANCE MARKET – LATIN AMERICA 128
17.1. Latin America 128
17.1.1. Key Highlights 128
17.1.2. Latin America Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 129
17.1.3. Latin America Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 130
17.1.4. Latin America Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 131
17.1.5. Latin America Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 132
17.1.6. Latin America Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 133
17.1.7. Latin America Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 134
17.1.8. Latin America Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 135
17.2. Brazil 136
17.3. Argentina 136
17.4. Peru 136
17.5. Chile 136
17.6. Colombia 136
17.7. Rest of Latin America 136
CHAPTER NO. 18 : PHARMACOVIGILANCE MARKET – MIDDLE EAST 137
18.1. Middle East 137
18.1.1. Key Highlights 137
18.1.2. Middle East Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 138
18.1.3. Middle East Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 139
18.1.4. Middle East Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 140
18.1.5. Middle East Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 141
18.1.6. Middle East Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 142
18.1.7. Middle East Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 143
18.1.8. Middle East Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 144
18.2. UAE 145
18.3. KSA 145
18.4. Israel 145
18.5. Turkey 145
18.6. Iran 145
18.7. Rest of Middle East 145
CHAPTER NO. 19 : PHARMACOVIGILANCE MARKET – AFRICA 146
19.1. Africa 146
19.1.1. Key Highlights 146
19.1.2. Africa Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 147
19.1.3. Africa Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 148
19.1.4. Africa Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 149
19.1.5. Africa Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 150
19.1.6. Africa Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 151
19.1.7. Africa Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 152
19.1.8. Africa Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 153
19.2. Egypt 154
19.3. Nigeria 154
19.4. Algeria 154
19.5. Morocco 154
19.6. Rest of Africa 154
CHAPTER NO. 20 : COMPANY PROFILES 155
20.1. Accenture 155
20.1.1. Company Overview 155
20.1.2. Product Portfolio 155
20.1.3. Swot Analysis 155
20.1.4. Business Strategy 156
20.1.5. Financial Overview 156
20.2. IQVIA Inc. 157
20.3. Cognizant 157
20.4. Clinquest Group B.V. (Linical Americas) 157
20.5. IBM 157
20.6. Laboratory Corporation of America Holdings 157
20.7. ArisGlobal 157
20.8. Capgemini 157
20.9. ITClinical 157
20.10. ICON plc. 157
20.11. TAKE Solutions Limited 157
20.12. Parexel International (MA) Corporation 157
20.13. Wipro 157
20.14. United BioSource LLC 157
20.15. BioClinica Inc. (Clario) 157
20.16. ClinChoice (formerly FMD K&L) 157
CHAPTER NO. 21 : RESEARCH METHODOLOGY 158
21.1. Research Methodology 158
21.1.1. Phase I – Secondary Research 159
21.1.2. Phase II – Data Modeling 159
Company Share Analysis Model 160
Revenue Based Modeling 160
21.1.3. Phase III – Primary Research 161
21.1.4. Research Limitations 162
Assumptions 162

List of Figures
FIG NO. 1. Global Pharmacovigilance Market Revenue, 2018 – 2032 (USD Million) 28
FIG NO. 2. Porter’s Five Forces Analysis for Global Pharmacovigilance Market 35
FIG NO. 3. Company Share Analysis, 2023 36
FIG NO. 4. Company Share Analysis, 2023 37
FIG NO. 5. Company Share Analysis, 2023 37
FIG NO. 6. Company Share Analysis, 2023 38
FIG NO. 7. Pharmacovigilance Market – Company Revenue Market Share, 2023 39
FIG NO. 8. Pharmacovigilance Market Revenue Share, By Product Life Cycle, 2023 & 2032 45
FIG NO. 9. Market Attractiveness Analysis, By Product Life Cycle 46
FIG NO. 10. Incremental Revenue Growth Opportunity by Product Life Cycle, 2024 – 2032 46
FIG NO. 11. Pharmacovigilance Market Revenue, By Product Life Cycle, 2018, 2023, 2027 & 2032 47
FIG NO. 12. Global Pharmacovigilance Market for Pre-clinical, Revenue (USD Million) 2018 – 2032 48
FIG NO. 13. Global Pharmacovigilance Market for Phase I, Revenue (USD Million) 2018 – 2032 49
FIG NO. 14. Global Pharmacovigilance Market for Phase II, Revenue (USD Million) 2018 – 2032 50
FIG NO. 15. Global Pharmacovigilance Market for Phase III, Revenue (USD Million) 2018 – 2032 51
FIG NO. 16. Global Pharmacovigilance Market for Phase IV, Revenue (USD Million) 2018 – 2032 52
FIG NO. 17. Pharmacovigilance Market Revenue Share, By Type, 2023 & 2032 54
FIG NO. 18. Market Attractiveness Analysis, By Type 55
FIG NO. 19. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 55
FIG NO. 20. Pharmacovigilance Market Revenue, By Type, 2018, 2023, 2027 & 2032 56
FIG NO. 21. Global Pharmacovigilance Market for Spontaneous Reporting, Revenue (USD Million) 2018 – 2032 57
FIG NO. 22. Global Pharmacovigilance Market for Intensified ADR Reporting, Revenue (USD Million) 2018 – 2032 58
FIG NO. 23. Global Pharmacovigilance Market for Targeted Spontaneous Reporting, Revenue (USD Million) 2018 – 2032 59
FIG NO. 24. Global Pharmacovigilance Market for Cohort Event Monitoring, Revenue (USD Million) 2018 – 2032 60
FIG NO. 25. Global Pharmacovigilance Market for EHR Mining, Revenue (USD Million) 2018 – 2032 61
FIG NO. 26. Pharmacovigilance Market Revenue Share, By Service Provider, 2023 & 2032 63
FIG NO. 27. Market Attractiveness Analysis, By Service Provider 64
FIG NO. 28. Incremental Revenue Growth Opportunity by Service Provider, 2024 – 2032 64
FIG NO. 29. Pharmacovigilance Market Revenue, By Service Provider, 2018, 2023, 2027 & 2032 65
FIG NO. 30. Global Pharmacovigilance Market for In-house, Revenue (USD Million) 2018 – 2032 66
FIG NO. 31. Global Pharmacovigilance Market for Contract Outsourcing, Revenue (USD Million) 2018 – 2032 67
FIG NO. 32. Pharmacovigilance Market Revenue Share, By End-use, 2023 & 2032 69
FIG NO. 33. Market Attractiveness Analysis, By End-use 70
FIG NO. 34. Incremental Revenue Growth Opportunity by End-use, 2024 – 2032 70
FIG NO. 35. Pharmacovigilance Market Revenue, By End-use, 2018, 2023, 2027 & 2032 71
FIG NO. 36. Global Pharmacovigilance Market for Pharmaceuticals, Revenue (USD Million) 2018 – 2032 72
FIG NO. 37. Global Pharmacovigilance Market for Biotechnology Companies, Revenue (USD Million) 2018 – 2032 73
FIG NO. 38. Global Pharmacovigilance Market for Medical Device Manufacturers, Revenue (USD Million) 2018 – 2032 74
FIG NO. 39. Global Pharmacovigilance Market for Others, Revenue (USD Million) 2018 – 2032 75
FIG NO. 40. Pharmacovigilance Market Revenue Share, By Process Flow, 2023 & 2032 77
FIG NO. 41. Market Attractiveness Analysis, By Process Flow 78
FIG NO. 42. Incremental Revenue Growth Opportunity by Process Flow, 2024 – 2032 78
FIG NO. 43. Pharmacovigilance Market Revenue, By Process Flow, 2018, 2023, 2027 & 2032 79
FIG NO. 44. Global Pharmacovigilance Market for Case Data Management, Revenue (USD Million) 2018 – 2032 80
FIG NO. 45. Global Pharmacovigilance Market for Case Logging, Revenue (USD Million) 2018 – 2032 80
FIG NO. 46. Global Pharmacovigilance Market for Case Data Analysis, Revenue (USD Million) 2018 – 2032 81
FIG NO. 47. Global Pharmacovigilance Market for Medical Reviewing & Reporting, Revenue (USD Million) 2018 – 2032 81
FIG NO. 48. Global Pharmacovigilance Market for Signal Detection, Revenue (USD Million) 2018 – 2032 82
FIG NO. 49. Global Pharmacovigilance Market for Adverse Event Logging, Revenue (USD Million) 2018 – 2032 82
FIG NO. 50. Global Pharmacovigilance Market for Adverse Event Analysis, Revenue (USD Million) 2018 – 2032 83
FIG NO. 51. Global Pharmacovigilance Market for Adverse Event Review & Reporting, Revenue (USD Million) 2018 – 2032 83
FIG NO. 52. Global Pharmacovigilance Market for Risk Management System, Revenue (USD Million) 2018 – 2032 84
FIG NO. 53. Global Pharmacovigilance Market for Risk Evaluation System, Revenue (USD Million) 2018 – 2032 84
FIG NO. 54. Global Pharmacovigilance Market for Risk Mitigation System, Revenue (USD Million) 2018 – 2032 85
FIG NO. 55. Pharmacovigilance Market Revenue Share, By Therapeutic Area, 2023 & 2032 87
FIG NO. 56. Market Attractiveness Analysis, By Therapeutic Area 88
FIG NO. 57. Incremental Revenue Growth Opportunity by Therapeutic Area, 2024 – 2032 88
FIG NO. 58. Pharmacovigilance Market Revenue, By Therapeutic Area, 2018, 2023, 2027 & 2032 89
FIG NO. 59. Global Pharmacovigilance Market for Oncology, Revenue (USD Million) 2018 – 2032 90
FIG NO. 60. Global Pharmacovigilance Market for Neurology, Revenue (USD Million) 2018 – 2032 91
FIG NO. 61. Global Pharmacovigilance Market for Cardiology, Revenue (USD Million) 2018 – 2032 92
FIG NO. 62. Global Pharmacovigilance Market for Respiratory Systems, Revenue (USD Million) 2018 – 2032 93
FIG NO. 63. Global Pharmacovigilance Market for Others, Revenue (USD Million) 2018 – 2032 94
FIG NO. 64. North America Pharmacovigilance Market Revenue, 2018 – 2032 (USD Million) 101
FIG NO. 65. Europe Pharmacovigilance Market Revenue, 2018 – 2032 (USD Million) 110
FIG NO. 66. Asia Pacific Pharmacovigilance Market Revenue, 2018 – 2032 (USD Million) 119
FIG NO. 67. Latin America Pharmacovigilance Market Revenue, 2018 – 2032 (USD Million) 128
FIG NO. 68. Middle East Pharmacovigilance Market Revenue, 2018 – 2032 (USD Million) 137
FIG NO. 69. Africa Pharmacovigilance Market Revenue, 2018 – 2032 (USD Million) 146
FIG NO. 70. Research Methodology – Detailed View 158
FIG NO. 71. Research Methodology 159

List of Tables
TABLE NO. 1. : Global Pharmacovigilance Market: Snapshot 26
TABLE NO. 2. : Drivers for the Pharmacovigilance Market: Impact Analysis 31
TABLE NO. 3. : Restraints for the Pharmacovigilance Market: Impact Analysis 33
TABLE NO. 4. : Global Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 95
TABLE NO. 5. : Global Pharmacovigilance Market Revenue, By Product Life Cycle, 2024 – 2032 (USD Million) 95
TABLE NO. 6. : Global Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 96
TABLE NO. 7. : Global Pharmacovigilance Market Revenue, By Type, 2024 – 2032 (USD Million) 96
TABLE NO. 8. : Global Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 97
TABLE NO. 9. : Global Pharmacovigilance Market Revenue, By Service Provider, 2024 – 2032 (USD Million) 97
TABLE NO. 10. : Global Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 98
TABLE NO. 11. : Global Pharmacovigilance Market Revenue, By End-use, 2024 – 2032 (USD Million) 98
TABLE NO. 12. : Global Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 99
TABLE NO. 13. : Global Pharmacovigilance Market Revenue, By Process Flow, 2024 – 2032 (USD Million) 99
TABLE NO. 14. : Global Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 100
TABLE NO. 15. : Global Pharmacovigilance Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 100
TABLE NO. 16. : North America Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 102
TABLE NO. 17. : North America Pharmacovigilance Market Revenue, By Country, 2024 – 2032 (USD Million) 102
TABLE NO. 18. : North America Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 103
TABLE NO. 19. : North America Pharmacovigilance Market Revenue, By Product Life Cycle, 2024 – 2032 (USD Million) 103
TABLE NO. 20. : North America Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 104
TABLE NO. 21. : North America Pharmacovigilance Market Revenue, By Type, 2024 – 2032 (USD Million) 104
TABLE NO. 22. : North America Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 105
TABLE NO. 23. : North America Pharmacovigilance Market Revenue, By Service Provider, 2024 – 2032 (USD Million) 105
TABLE NO. 24. : North America Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 106
TABLE NO. 25. : North America Pharmacovigilance Market Revenue, By End-use, 2024 – 2032 (USD Million) 106
TABLE NO. 26. : North America Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 107
TABLE NO. 27. : North America Pharmacovigilance Market Revenue, By Process Flow, 2024 – 2032 (USD Million) 107
TABLE NO. 28. : North America Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 108
TABLE NO. 29. : North America Pharmacovigilance Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 108
TABLE NO. 30. : Europe Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 111
TABLE NO. 31. : Europe Pharmacovigilance Market Revenue, By Country, 2024 – 2032 (USD Million) 111
TABLE NO. 32. : Europe Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 112
TABLE NO. 33. : Europe Pharmacovigilance Market Revenue, By Product Life Cycle, 2024 – 2032 (USD Million) 112
TABLE NO. 34. : Europe Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 113
TABLE NO. 35. : Europe Pharmacovigilance Market Revenue, By Type, 2024 – 2032 (USD Million) 113
TABLE NO. 36. : Europe Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 114
TABLE NO. 37. : Europe Pharmacovigilance Market Revenue, By Service Provider, 2024 – 2032 (USD Million) 114
TABLE NO. 38. : Europe Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 115
TABLE NO. 39. : Europe Pharmacovigilance Market Revenue, By End-use, 2024 – 2032 (USD Million) 115
TABLE NO. 40. : Europe Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 116
TABLE NO. 41. : Europe Pharmacovigilance Market Revenue, By Process Flow, 2024 – 2032 (USD Million) 116
TABLE NO. 42. : Europe Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 117
TABLE NO. 43. : Europe Pharmacovigilance Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 117
TABLE NO. 44. : Asia Pacific Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 120
TABLE NO. 45. : Asia Pacific Pharmacovigilance Market Revenue, By Country, 2024 – 2032 (USD Million) 120
TABLE NO. 46. : Asia Pacific Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 121
TABLE NO. 47. : Asia Pacific Pharmacovigilance Market Revenue, By Product Life Cycle, 2024 – 2032 (USD Million) 121
TABLE NO. 48. : Asia Pacific Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 122
TABLE NO. 49. : Asia Pacific Pharmacovigilance Market Revenue, By Type, 2024 – 2032 (USD Million) 122
TABLE NO. 50. : Asia Pacific Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 123
TABLE NO. 51. : Asia Pacific Pharmacovigilance Market Revenue, By Service Provider, 2024 – 2032 (USD Million) 123
TABLE NO. 52. : Asia Pacific Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 124
TABLE NO. 53. : Asia Pacific Pharmacovigilance Market Revenue, By End-use, 2024 – 2032 (USD Million) 124
TABLE NO. 54. : Asia Pacific Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 125
TABLE NO. 55. : Asia Pacific Pharmacovigilance Market Revenue, By Process Flow, 2024 – 2032 (USD Million) 125
TABLE NO. 56. : Asia Pacific Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 126
TABLE NO. 57. : Asia Pacific Pharmacovigilance Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 126
TABLE NO. 58. : Latin America Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 129
TABLE NO. 59. : Latin America Pharmacovigilance Market Revenue, By Country, 2024 – 2032 (USD Million) 129
TABLE NO. 60. : Latin America Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 130
TABLE NO. 61. : Latin America Pharmacovigilance Market Revenue, By Product Life Cycle, 2024 – 2032 (USD Million) 130
TABLE NO. 62. : Latin America Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 131
TABLE NO. 63. : Latin America Pharmacovigilance Market Revenue, By Type, 2024 – 2032 (USD Million) 131
TABLE NO. 64. : Latin America Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 132
TABLE NO. 65. : Latin America Pharmacovigilance Market Revenue, By Service Provider, 2024 – 2032 (USD Million) 132
TABLE NO. 66. : Latin America Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 133
TABLE NO. 67. : Latin America Pharmacovigilance Market Revenue, By End-use, 2024 – 2032 (USD Million) 133
TABLE NO. 68. : Latin America Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 134
TABLE NO. 69. : Latin America Pharmacovigilance Market Revenue, By Process Flow, 2024 – 2032 (USD Million) 134
TABLE NO. 70. : Latin America Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 135
TABLE NO. 71. : Latin America Pharmacovigilance Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 135
TABLE NO. 72. : Middle East Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 138
TABLE NO. 73. : Middle East Pharmacovigilance Market Revenue, By Country, 2024 – 2032 (USD Million) 138
TABLE NO. 74. : Middle East Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 139
TABLE NO. 75. : Middle East Pharmacovigilance Market Revenue, By Product Life Cycle, 2024 – 2032 (USD Million) 139
TABLE NO. 76. : Middle East Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 140
TABLE NO. 77. : Middle East Pharmacovigilance Market Revenue, By Type, 2024 – 2032 (USD Million) 140
TABLE NO. 78. : Middle East Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 141
TABLE NO. 79. : Middle East Pharmacovigilance Market Revenue, By Service Provider, 2024 – 2032 (USD Million) 141
TABLE NO. 80. : Middle East Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 142
TABLE NO. 81. : Middle East Pharmacovigilance Market Revenue, By End-use, 2024 – 2032 (USD Million) 142
TABLE NO. 82. : Middle East Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 143
TABLE NO. 83. : Middle East Pharmacovigilance Market Revenue, By Process Flow, 2024 – 2032 (USD Million) 143
TABLE NO. 84. : Middle East Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 144
TABLE NO. 85. : Middle East Pharmacovigilance Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 144
TABLE NO. 86. : Africa Pharmacovigilance Market Revenue, By Country, 2018 – 2023 (USD Million) 147
TABLE NO. 87. : Africa Pharmacovigilance Market Revenue, By Country, 2024 – 2032 (USD Million) 147
TABLE NO. 88. : Africa Pharmacovigilance Market Revenue, By Product Life Cycle, 2018 – 2023 (USD Million) 148
TABLE NO. 89. : Africa Pharmacovigilance Market Revenue, By Product Life Cycle, 2024 – 2032 (USD Million) 148
TABLE NO. 90. : Africa Pharmacovigilance Market Revenue, By Type, 2018 – 2023 (USD Million) 149
TABLE NO. 91. : Africa Pharmacovigilance Market Revenue, By Type, 2024 – 2032 (USD Million) 149
TABLE NO. 92. : Africa Pharmacovigilance Market Revenue, By Service Provider, 2018 – 2023 (USD Million) 150
TABLE NO. 93. : Africa Pharmacovigilance Market Revenue, By Service Provider, 2024 – 2032 (USD Million) 150
TABLE NO. 94. : Africa Pharmacovigilance Market Revenue, By End-use, 2018 – 2023 (USD Million) 151
TABLE NO. 95. : Africa Pharmacovigilance Market Revenue, By End-use, 2024 – 2032 (USD Million) 151
TABLE NO. 96. : Africa Pharmacovigilance Market Revenue, By Process Flow, 2018 – 2023 (USD Million) 152
TABLE NO. 97. : Africa Pharmacovigilance Market Revenue, By Process Flow, 2024 – 2032 (USD Million) 152
TABLE NO. 98. : Africa Pharmacovigilance Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 153
TABLE NO. 99. : Africa Pharmacovigilance Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 153

What is the current size of the Global Pharmacovigilance Market?

The Global Pharmacovigilance Market is valued at USD 9,574.26 million as of 2023.

What factors are driving the growth of the Global Pharmacovigilance Market?

The market is primarily driven by increasing regulatory requirements for drug safety, rising consumer awareness about adverse drug reactions, and the growing complexity of drug development processes. Additionally, the integration of advanced technologies like AI and big data analytics, and the increasing number of clinical trials and chronic disease incidence globally, further stimulate the demand for robust pharmacovigilance systems.

What are the key segments within the Global Pharmacovigilance Market?

Key segments within the market include different stages of the product life cycle (Pre-clinical, Phase I, II, III, IV), types of reporting and monitoring (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining), as well as divisions by service provider, end-use, process flow, therapeutic area, and geography.

What are some challenges faced by the Global Pharmacovigilance Market?

Major challenges include ensuring high data quality and completeness across diverse sources, maintaining privacy and security in line with stringent regulations like GDPR and HIPAA, and overcoming global harmonization and technological adoption challenges. These include disparities in regulations across regions and the high costs and technical demands of implementing advanced technologies.

Who are the major players in the Global Pharmacovigilance Market?

Key players in the market include Accenture, IQVIA Inc., Cognizant, ICON plc., Clinquest Group B.V. (Linical Americas), Parexel International (MA) Corporation, and others. These companies drive innovation and offer comprehensive pharmacovigilance solutions, leveraging global reach and technological advancements to enhance drug safety monitoring and regulatory compliance.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –